A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subject With Critical Limb Ischemia
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions
- Sponsors ViroMed
- 03 Aug 2017 Results from this trial have been published in the journal Gene Therapy, according to a VM BioPharma media release.
- 22 Jan 2016 Results published in a ViroMed Co. media release.
- 28 Jan 2015 Primary endpoint, trial focus and the time frame for endpoint changed as reported by ClinicalTrials.gov record.